Modern Retina

Your top destination for retina-related information. We provide insights on conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, uveitis, and others. We are partnered with Ophthalmology Times.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1181897

United States

#791820

Health/Medicine

#4771

Traffic sources

Monthly visitors

Articles

Next-generation retinal disease treatments: Advancing care in nAMD and DME

5 days ago | modernretina.com | Lynda Charters

Michael A. Klufas, MD, of the retina service at Wills Eye Hospital in Philadelphia, Pennsylvania, presented 3 cases and discussed how second-generation retinal vascular agents, such as high-dose aflibercept 8 mg (Eylea HD; Regeneron Pharmaceuticals, Inc) and faricimab (Vabysmo; Genentech), show promising results for treating these 2 common disorders.
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA

1 week ago | modernretina.com | Martin Harp

June 20, 2025The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease. Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to begin a phase 2/3 pivotal confirmatory trial of OCU410ST. OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.
Genetic link found between instant coffee consumption and dry AMD

1 week ago | modernretina.com | Lynda Charters

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD). Of particular note is that instant coffee may increase the risk of development of dry AMD. Reducing its intake could help prevent dry AMD. People at high‐risk for AMD should avoid instant coffee,1 according to first author Qi Jia, MD, from theDepartment of Ophthalmology, Shiyan Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy

1 week ago | modernretina.com | Martin Harp

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory body for cosmetics, pharmaceuticals, and medical devices, for permission to start phase 2 of the study.
Pattern laser indirect ophthalmoscope in first 10 patients

1 week ago | modernretina.com | Lynda Charters

Nassim Abreu, MD, reported the initial experience while applying panretinal photocoagulation (PRP) using the new LYNX pattern laser indirect ophthalmoscope (LIO) (Norlase). Abreu, who is an associate professor in the Retina Department of Elias Santana Hospital, Santo Domingo, Dominican Republic, described the technology and its performance at the Retina World Congress in Fort Lauderdale, FL. The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.
Sustained anti-VEGF therapy: Pros and cons of the PDS for treating retinal disease

1 week ago | modernretina.com | Lynda Charters

Yasha Modi, MD, from NYU Langone Health, New York, New York, and Carl Danzig, MD, from the Rand Eye Institute, Deerfield Beach, Florida, participated in an opinion panel for Modern Retina. They discussed the clinical benefits, clinical trial results, surgical considerations, and factors affecting clinician decision-making regarding the Port Delivery System (PDS) with ranibizumab injection (Susvimo; Genentech) in clinical practice.
EyeCare Partners releases Quality and Outcomes Report, highlights optometric successes

1 week ago | modernretina.com | Jordana Joy

EyeCare Partners (ECP) has released its first ever Quality and Outcomes Report, a comprehensive publication that outlines the organization’s highlights from 2024 in terms of clinical successes, innovation, research, and patient outcomes, according to a news release.1 The report evaluates both the organization’s ophthalmology and optometry business units, in addition to education, eye care provider profiles, and patient stories, among others.2 “The release of our inaugural Quality and Outcomes...
Early diabetic retinopathy detection may be found in biomarker changes

2 weeks ago | modernretina.com | Lynda Charters

An Indonesian study of the characteristics of the retinal vasculature found that the retinal vessel tortuosity (VT) was significantly higher and the fractal dimension (FD) was significantly lower in patients with diabetic retinopathy (DR) compared with those without DR.1 Lead author Fariztah Sukainah Nur Fathimah, MD, from the Department of Ophthalmology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia, and colleagues reported their findings in the International...
HIV drug lamivudine holds potential for patients with DME, researchers find

2 weeks ago | modernretina.com | Jordana Joy

Researchers have discovered that a long-approved HIV drug has the potential to improve vision in patients with diabetic macular edema (DME).1 Researcher Jayakrishna Ambati, MD, founding director of UVA Health’s Center for Advanced Vision Science, alongside collaborators at Brazil’s Universidade Federal de São Paulo led by Dr. Felipe Pereira and Dr. Eduardo Buchele Rodrigues, found that lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients, according...
ZEISS fundus imaging device receives NMPA approval in China

2 weeks ago | modernretina.com | Jordana Joy

ZEISS Medical Technology’s fundus imaging device CLARUS 700 has received National Medical Products Administration (NMPA) approval in China.1 The device, which utilizes fluorescein angiography, will allow eye care providers in China to capture ultra-widefield, high-resolution images of the retina, according to a news release. “ZEISS CLARUS 700 represents a major step forward in retinal imaging," said Anuj Kalra, head of Chronic Disease Management at ZEISS, in the release.